Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Degarelix and TULSA in Intermediate-risk Prostate Cancer
NCT05917860Phase 1Active, not recruiting
- Sponsor
- Turku University Hospital
- Start
- Jul 2023
- Primary completion
- Jan 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of degarelix in prostate cancer (PCa), sponsored by Turku University Hospital. Primary endpoints: Change in prostate volume after neoadjuvant ADT at 12 weeks, Change in prostate tumor volume after neoadjuvant ADT at 12 weeks and 1 more. Started Jul 2023; status: active, not recruiting.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05917860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05917860.